ARIAD Announces Broader Profile of Its Investigational Lung Cancer Drug Candidate, AP26113, Showing Dual Inhibition of ALK and EGFR - New Preclinical Data Highlight Potential in Resistant Lung Cancer Due to Mutated EGFR